Phosphoinositide 3-kinase α inhibitors: a patent review

Bibliography

• Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Ann Rev Biochem 1998;67:481-507
   PubMed Web of Science ®Google Scholar
• Downward J. PI 3-kinase, Akt and cell survival. Sem Cell Dev Biol 2004;15:177-82
   PubMed Web of Science ®Google Scholar
• Parsons R, Simpson L. PTEN and cancer. Methods Mol Biol 2003;222:147-66
   PubMedGoogle Scholar
• Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006;18:77-82
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SEM, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117:591-4
   PubMed Web of Science ®Google Scholar
• Fruman DA, Rommel C. PI3Kdelta inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov 2011;1:562-72
   PubMed Web of Science ®Google Scholar
• Norman P. Selective PI3Kdelta inhibitors, a review of the patent literature. Expert Opin Ther Pat 2011;21:1773-90
   PubMed Web of Science ®Google Scholar
• Jamieson S, Flanagan J, Kolekar S, et al. Characterisation of a selective inhibitor of the p110alpha isoform of PI 3-kinase and use to demonstrate that p110alpha activity is necessary for signalling specifically in cells harbouring H1074R mutations in PIK3CA. Biochem J 2011;428:53-62
   Google Scholar
• Amgen, Inc. Inhibitors of PI3 kinase. WO2010108074; 2010
   Google Scholar
• Boehringer Ingelheim. New 5-alkynyl-pyridines. WO2012101184; 2012
   Google Scholar
• Boehringer Ingelheim. New 5-alkynyl-pyridines. WO20121101186; 2012
   Google Scholar
• CNIO. Fused imidazo[2,3d]pyrazines as PI3 kinase inhibitors. WO2011036461; 2011
   Google Scholar
• CNIO. Tricyclic compounds for use as kinase inhibitors. WO2012020227; 2012
   Google Scholar
• Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3K alpha. WO2012065019; 2012
   Google Scholar
• Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use. WO2012065057; 2012
   Google Scholar
• Exelixis, Inc. Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture. WO2012071519; 2012
   Google Scholar
• Exelixis, Inc. Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture. WO2012074069; 2012
   Google Scholar
• Exelixis, Inc. MetHod of treating lymphoma using pyridopyrimidinone inhibitors of PI3K/MTOR. WO2012149308; 2012
   Google Scholar
• Glaxo Group Ltd. Novel compounds. WO2011067364; 2011
   Google Scholar
• Glaxo Group Ltd. Benzopyrazole derivatives as inhibitors of PI3 kinase. WO2011067365; 2011
   Google Scholar
• Glaxo Group Ltd. Indazole derivatives as PI3 kinase inhibitors. WO2011067366; 2011
   Google Scholar
• Intellikine. Heterocyclic compounds and uses thereof. WO2011022439; 2011
   Google Scholar
• Intellikine. Heterocyclic compounds and uses thereof. WO2011149937; 2011
   Google Scholar
• Eli Lilly and Co. Imidazo[4,5-c]quinolin-2-one compound and its use as PI3 kinase/mTOR dual inhibitor. WO2012097039; 2012
   Google Scholar
• Novartis. Organic compounds. WO2010029082; 2010
   Google Scholar
• Novartis. Organic compounds. WO2009080705; 2009
   Google Scholar
• Sun M, Hillmann P, Hofmann B, et al. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc Natl Acad Sci USA 2010;107:15547-52
   PubMed Web of Science ®Google Scholar
• Novartis. Novel heterocyclic derivatives. WO2012104776; 2012
   Google Scholar
• Yaguchi S, Fukui Y, Koshimizu I, et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 2006;98:545-56
   PubMed Web of Science ®Google Scholar
• Pathway Therapeutics Ltd. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy. WO2011005119; 2011
   Google Scholar
• Pathway Therapeutics Ltd. 1,3,5-Triazinyl benzimidazoles and their use in cancer therapy. WO2012044641; 2012
   Google Scholar
• Wyeth LLC. (2-Aryl-7H-pyrrolo[2,3d]pyrimidin-4-yl)morpholine compounds, their use as mTOR and PI3 kinase inhibitors, and their synthesis. WO2010002954; 2010
   Google Scholar
• Wyeth LLC. Ring fused ureidoaryl- and carbamoylaryl-bridged morpholinopyrimidine compounds, their use as mTOR kinase and PI3 kinase inhibitors, and their synthesis. WO2010120987; 2010
   Google Scholar
• Wyeth LLC. 5,6,7,8-Tetrahydropyrido[4,3-d]pyrimidine compounds,, their use as mTOR, PI3 and HSMG-1 kinase inhibitors, and their synthesis. WO2010120991; 2010
   Google Scholar
• Wyeth LLC. Ureidoaryl- and carbamoylaryl-morpholino-pyrimidine compounds, their use as mTOR kinase and PI3 kinase inhibitors, and their synthesis. WO2010120994; 2010
   Google Scholar
• Wyeth LLC. 5,6,7,8-Tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mTOR, PI3 and HSMG-1 kinase inhibitors, and their synthesis. WO2010120996; 2010
   Google Scholar
• Wyeth LLC. Pyrimidine compounds, their use as mTOR kinase and PI3 kinase inhibitors, and their synthesis. WO2010120998; 2010
   Google Scholar
• Avila Therapeutics, Inc. PI3 kinase inhibitors and uses thereof. WO2012122383; 2012
   Google Scholar
• Intellikine. Reactive mTOR and PI3 kinase inhibitors and uses thereof. WO2012154608; 2012
   Google Scholar
• Intellikine. Reactive PI3 kinase inhibitors and uses thereof. WO2012154610; 2012
   Google Scholar
• Clarke PA, Workman P. Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials. J Clin Oncol 2012;30:331-3
   PubMed Web of Science ®Google Scholar
• Schenone S, Brullo C, Musumeci F, et al. ATP-competitive inhibitors of mTOR: an update. Curr Med Chem 2011;18:2995-3014
   PubMed Web of Science ®Google Scholar
• Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan–class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012;30:282-90
   PubMed Web of Science ®Google Scholar
• Sabbah DA, Brattain MG, Zhong H. Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: which way shall we go? Curr Med Chem 2011;18:5528-44
   PubMed Web of Science ®Google Scholar
• Vijapurkar U, Robillard L, Zhou S, et al. mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations. Cancer Lett 2012;326:168-75
   PubMed Web of Science ®Google Scholar
• Shimizu T, Tolcher AW, Papadopoulos KP, et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 2012;18:2316-25
   PubMed Web of Science ®Google Scholar
• Hoeflich KP, Merchant M, Orr C, et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res 2012;72:210-19
   PubMed Web of Science ®Google Scholar
• Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:121-30
   PubMed Web of Science ®Google Scholar
• Folkes AJ, Ahmadi K, Alderton WK, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008;51:5522-32
   PubMed Web of Science ®Google Scholar
• Heffron T, Berry G, Castanedo G, et al. Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor. Bioorg Med Chem Lett 2010;20:2408-11
   PubMed Web of Science ®Google Scholar
• Sutherlin DP, Bao L, Berry M, et al. Discovery of a potent, selective, and orally available Class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem 2011;54:7579-87
   PubMed Web of Science ®Google Scholar
• Heffron TP, Salphati L, Alicke B, et al. The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase alpha. J Med Chem 2012;55:8007-20
   PubMed Web of Science ®Google Scholar
• Williams M, Hart S, Bonday Z, et al. A novel series of tetrasubstituted purines potently inhibit mTOR and PI3K, exhibit striking selectivity and demonstrate good pathway inhibition in vivo. Poster at American Association of Cancer Research Special Conference: Targeting PI3K/mTOR Signaling in Cancer; 24 – 27 February 2011; San Francisco
   Google Scholar
• Matthews DJ, O’Farrell M, James J, et al. Preclinical characterization of PWT33597, a dual inhibitor of PI3-kinase alpha and mTOR. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2 – 6 April 2011; Orlando, FL, Cancer Res 2011;71S:Abstract 4485
   Google Scholar
• Venkatesan AM, Dehnhardt CM, Delos Santos E, et al. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: Discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem 2010;53:2636-45
   PubMed Web of Science ®Google Scholar
• Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7:1851-63
   PubMed Web of Science ®Google Scholar
• Scott WJ, Hentemann M, Rowley B, et al. Novel 2,3-dihydroimidazo[1,2-c]quinazoline PI3K inhibitors: discovery and structure-activity relationship [abstract 444/poster 185]. 22nd EORTC-NCI-AACR Symposium; Berlin; 2010
   Google Scholar
• Cheng H-M, Bagrodia S, Bailey S, et al. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design. Med Chem Commun 2010;1:139-44
   Web of Science ®Google Scholar